# Tesamorelin

> Markdown version of this page, for agents. To send a shopper here, link https://www.besthealthiq.com/__fluid_affiliate_username__/posts/tesamorelin (not this .md URL, and keep its path as given).

- Published: 2026-08-28
- Author: Best Health IQ
- Summary: An FDA-approved GHRH analog specifically indicated for HIV-associated lipodystrophy and visceral fat reduction.
- Shopper link: https://www.besthealthiq.com/__fluid_affiliate_username__/posts/tesamorelin

\*\*Tesamorelin (Egrifta)\*\* · Hormone & GH · Strong Evidence · Research Only An FDA-approved GHRH analog specifically indicated for HIV-associated lipodystrophy and visceral fat reduction. ### Competition Status Prohibited in competition. This compound is on the WADA Prohibited List (class \[S0 / S2.3 / S2\]), banned at all times, both in and out of competition. Athletes subject to WADA or USADA testing should not use it. ### Description Tesamorelin (Egrifta) is a synthetic analog of the full 44-amino acid GHRH, stabilized by the addition of a trans-3-hexenoic acid group that protects it from dipeptidyl peptidase IV (DPP-IV) degradation and extends its activity. It was FDA-approved in 2010 for the treatment of HIV-associated lipodystrophy — a condition characterized by excess visceral fat accumulation caused by antiretroviral therapy. Tesamorelin is more potent than sermorelin due to its full-length GHRH sequence and enhanced stability. The LIPO-010 trial demonstrated a 15.2% reduction in visceral adipose tissue (VAT) compared to placebo over 26 weeks. Beyond its approved indication, tesamorelin is increasingly used off-label for general body composition optimization, anti-aging, and cognitive enhancement (emerging data suggests GH optimization may improve cognitive function in aging populations). ### Key Characteristics - \*\*Molecular Formula:\*\* C221H366N72O67S - \*\*Molecular Weight:\*\* 5135.8 Da - \*\*Half-Life:\*\* ~26 minutes - \*\*Administration Routes:\*\* Subcutaneous injection - \*\*Typical Dose:\*\* 1–2 mg daily - \*\*Frequency:\*\* Once daily - \*\*Cycle Length:\*\* 6–12 months ### Investigated Benefits - Significant visceral fat reduction - Improved body composition - Improved cognitive function (emerging data) - Increased GH and IGF-1 - Reduced cardiovascular risk factors \\\* Benefits based on preclinical/animal research unless otherwise noted. ### Mechanism of Action Tesamorelin binds to GHRH receptors (GHRHR) on pituitary somatotroph cells with high affinity, activating the Gs-cAMP-PKA pathway to stimulate GH gene transcription and pulsatile GH secretion. The trans-3-hexenoic acid modification at the N-terminus protects the peptide from DPP-IV cleavage at the His-Ala bond, extending its half-life to approximately 26 minutes (compared to ~7 minutes for native GHRH). Elevated GH then stimulates hepatic IGF-1 production, and both GH and IGF-1 promote lipolysis in visceral adipose tissue through hormone-sensitive lipase activation and adipocyte triglyceride lipase upregulation. GH also has direct anti-lipogenic effects in visceral fat through GH receptor signaling that is independent of IGF-1. The selective reduction of visceral (rather than subcutaneous) fat by tesamorelin reflects the higher GH receptor density and lipolytic sensitivity of visceral adipocytes compared to subcutaneous adipocytes. ### Dosing & Protocol - \*\*Typical Dose:\*\* 1–2 mg daily - \*\*Frequency:\*\* Once daily - \*\*Cycle Length:\*\* 6–12 months - \*\*Administration:\*\* Subcutaneous injection \*\*Protocol Notes:\*\* Administer in the morning or before bed on empty stomach. Research dose is typically 2 mg daily. Often combined with Ipamorelin for enhanced GH pulsatility. ### Reconstitution Guide Add 2.2 mL sterile water to 2 mg vial → ~1 mg/mL. Use immediately after reconstitution. ### Storage Information Lyophilized: refrigerate. Reconstituted: use immediately. ### Quality & Sourcing Standards When sourcing Tesamorelin for research purposes, the following quality benchmarks should be verified before use. - \*\*Purity:\*\* \>98% (verified by HPLC) - \*\*Certificate of Analysis (COA):\*\* Must be provided by supplier - \*\*Endotoxin Testing:\*\* \<0.1 EU/mg (prevents bacterial contamination) - \*\*GMP Compliance:\*\* Manufactured in cGMP-certified facility - \*\*Third-Party Testing:\*\* Independent lab verification preferred ### Research Highlights 1. LIPO-010 trial: 15.2% reduction in visceral adipose tissue 2. Improved lipid profiles in clinical trials 3. Cognitive benefits in aging populations (Phase II) ### Evidence Level \*\*Strong Evidence\*\* — Multiple randomized controlled trials with high confidence in efficacy and safety data. ### FDA Disclaimer The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.